Genomic Investigation of Unusual Responders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-01

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The present protocol seeks to retrospectively perform Exome, next-generation (DNA) sequencing and/or other molecular techniques on tumor samples to identify the genetic basis of a patient's exceptional response to chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genomic Profiling in Cancer Patients

NCT01775072

Solid Tumors Hematologic Cancers

RECRUITING

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

NCT03707574

Advanced Malignant Neoplasm Advanced Melanoma Advanced Renal Cell Carcinoma +51 more

ACTIVE_NOT_RECRUITING

Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma

NCT02251314

Melanoma

COMPLETED

Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples

NCT01703585

Colorectal Cancer Breast Cancer Gynecological Cancer +3 more

COMPLETED

Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma

NCT00450593

Hereditary Multiple Melanoma Melanoma (Skin)

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Breast Cancer Non-small Cell Lung Cancer Colorectal Cancer Genitourinary Cancer Gynecological Cancer Upper Aerodigestive Tract Cancer Pancreatobiliary Gastrointestinal Cancer Melanoma (Skin) Rare Cancer Carcinoma of Unknown Primary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The patient must have either an exceptionally good or poor response to treatment, as indicated by their treating physician.

1. The exact definition of this is adaptable to the disease but a suggested guideline is a Complete Response, Partial Response or progression free interval of at least 6 months
2. Exceptionally poor response includes patients who were expected to respond favourably to a treatment but instead responded poorly (e.g dramatic tumor growth or death)
2. The patient must have sufficient archival tumor available for sequencing.
3. Deceased patients will also be considered for analysis (up to 30 patients per year) if they meet at least one of the following requirements:

a)) Patients who have archival tissue stored within the UHN Laboratory Medicine Program who have had a consent waiver granted by the REB to access the tissue.

b) Patients who have archival tissue banked for further research within the UHN Biospecimen Sciences Program